NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
Clinical Trials
12 trialsNCT03237325 2022-11-08
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Soligenix
Phase 3 Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02399228 2021-11-19
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
Santalis Pharmaceuticals, Inc.
Phase 2 Completed
NCT01403064 2021-05-11
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
Phase 2 Terminated
NCT03234465 2020-11-23
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Oragenics, Inc.
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02013050 2017-08-28
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Soligenix
Phase 2 Completed
NCT00101582 2016-09-27
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Swedish Orphan Biovitrum
Phase 3 Completed
NCT00460421 2014-12-05
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Swedish Orphan Biovitrum
Phase 1 Completed
NCT00189488 2014-09-15
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Swedish Orphan Biovitrum
Phase 2 Completed
NCT00385515 2009-05-07
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Mucosal Therapeutics
Phase 2 Completed